| pubmed-article:18784242 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18784242 | lifeskim:mentions | umls-concept:C0040802 | lld:lifeskim |
| pubmed-article:18784242 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:18784242 | lifeskim:mentions | umls-concept:C0023343 | lld:lifeskim |
| pubmed-article:18784242 | lifeskim:mentions | umls-concept:C0442592 | lld:lifeskim |
| pubmed-article:18784242 | lifeskim:mentions | umls-concept:C0443286 | lld:lifeskim |
| pubmed-article:18784242 | lifeskim:mentions | umls-concept:C0596545 | lld:lifeskim |
| pubmed-article:18784242 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:18784242 | pubmed:dateCreated | 2008-9-11 | lld:pubmed |
| pubmed-article:18784242 | pubmed:abstractText | Very few data have been reported on the epidemiology and clinical features of leprosy reactions in non-endemic settings. We performed a retrospective descriptive analysis to define the frequency and features of Type 1 and Type 2 leprosy reactions in a cohort of patients followed at a US travel and tropical medicine clinic in a 5-year period. We identified that leprosy reactions presented in 10/14 (71.4%) patients with leprosy seen at our clinic. We identified that leprosy reactions occur frequently among patients living in non-endemic areas and may occur before the initiation of multi-drug therapy (MDT), during MDT, or even years after completion of therapy and may produce significant neurologic sequelae. This group of patients needs long-term clinical monitoring even after completion of MDT because of the need to continue either anti-inflammatory therapy, presence of severe neurologic sequelae after reactions, or the potential occurrence of late leprosy reactions. | lld:pubmed |
| pubmed-article:18784242 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18784242 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18784242 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:18784242 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18784242 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18784242 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:18784242 | pubmed:issn | 1476-1645 | lld:pubmed |
| pubmed-article:18784242 | pubmed:author | pubmed-author:Franco-Parede... | lld:pubmed |
| pubmed-article:18784242 | pubmed:author | pubmed-author:LeonardMichae... | lld:pubmed |
| pubmed-article:18784242 | pubmed:author | pubmed-author:DismukesRober... | lld:pubmed |
| pubmed-article:18784242 | pubmed:author | pubmed-author:KozarskyPhyll... | lld:pubmed |
| pubmed-article:18784242 | pubmed:author | pubmed-author:TellezIldefon... | lld:pubmed |
| pubmed-article:18784242 | pubmed:author | pubmed-author:JacobJesse... | lld:pubmed |
| pubmed-article:18784242 | pubmed:author | pubmed-author:BynoeVickiV | lld:pubmed |
| pubmed-article:18784242 | pubmed:author | pubmed-author:MargolesLinds... | lld:pubmed |
| pubmed-article:18784242 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18784242 | pubmed:volume | 79 | lld:pubmed |
| pubmed-article:18784242 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18784242 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18784242 | pubmed:pagination | 452-4 | lld:pubmed |
| pubmed-article:18784242 | pubmed:meshHeading | pubmed-meshheading:18784242... | lld:pubmed |
| pubmed-article:18784242 | pubmed:meshHeading | pubmed-meshheading:18784242... | lld:pubmed |
| pubmed-article:18784242 | pubmed:meshHeading | pubmed-meshheading:18784242... | lld:pubmed |
| pubmed-article:18784242 | pubmed:meshHeading | pubmed-meshheading:18784242... | lld:pubmed |
| pubmed-article:18784242 | pubmed:meshHeading | pubmed-meshheading:18784242... | lld:pubmed |
| pubmed-article:18784242 | pubmed:meshHeading | pubmed-meshheading:18784242... | lld:pubmed |
| pubmed-article:18784242 | pubmed:meshHeading | pubmed-meshheading:18784242... | lld:pubmed |
| pubmed-article:18784242 | pubmed:meshHeading | pubmed-meshheading:18784242... | lld:pubmed |
| pubmed-article:18784242 | pubmed:meshHeading | pubmed-meshheading:18784242... | lld:pubmed |
| pubmed-article:18784242 | pubmed:meshHeading | pubmed-meshheading:18784242... | lld:pubmed |
| pubmed-article:18784242 | pubmed:meshHeading | pubmed-meshheading:18784242... | lld:pubmed |
| pubmed-article:18784242 | pubmed:meshHeading | pubmed-meshheading:18784242... | lld:pubmed |
| pubmed-article:18784242 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18784242 | pubmed:articleTitle | Five-year experience with type 1 and type 2 reactions in Hansen disease at a US travel clinic. | lld:pubmed |
| pubmed-article:18784242 | pubmed:affiliation | Division of Infectious Diseases, Emory University, Atlanta, Georgia, USA. frs7@cdc.gov | lld:pubmed |
| pubmed-article:18784242 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18784242 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
